Unique ID issued by UMIN | UMIN000051414 |
---|---|
Receipt number | R000058527 |
Scientific Title | Safety of intensive downstaging polypectomy (IDP) with low power pure-cut current (LPPC) in patients with familial adenomatous polyposis (FAP) |
Date of disclosure of the study information | 2023/06/23 |
Last modified on | 2024/06/21 13:00:02 |
Safety of intensive downstaging polypectomy with low power pure-cut current in patients with familial adenomatous polyposis
Safety of intensive downstaging polypectomy with low power pure-cut current in patients with familial adenomatous polyposis
Safety of intensive downstaging polypectomy (IDP) with low power pure-cut current (LPPC) in patients with familial adenomatous polyposis (FAP)
Safety of intensive downstaging polypectomy with low power pure-cut current in patients with familial adenomatous polyposis
Japan |
Familial adenomatous polyposis
Gastroenterology |
Others
NO
To clarify the safety of intensive downstaging polypectomy with low power pure-cut current in patients with familial adenomatous polyposis
Safety
Exploratory
Phase II
Incidence of severe adverse events (delayed bleeding and perforation)
adverse events related to IDP, procedure time, degree of abdominal pain on the day following IDP, presence of hematochezia after IDP, emergency colonoscopy and readmission to the hospital
Observational
18 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Patients diagnosed with familial adenomatous polyposis and undergoing or scheduled to undergo IDP
2) Those who have not undergo colectomy, or those who had undergone colectomy and had 10 cm or more of large intestine remaining
3) Patients aged 18 to 80 years old
4) Patients with ECOG PS 0 or 1
5) Patients with written informed consent
1) Patients known to have colorectal lesion larger than 15 mm
2) Those who had dense polyps
3) Patients with serious other organ disease
4) Patients continuing antithrombotic drugs, for whom IDP should not be carried out according to the Japanese guidelines
5) Patients continuing systemic administration of steroid
6) Patients receiving anticancer agents
7) Those who have psychosis or psychiatric symptoms that would make participation in the study difficult
8) Patients with active infection disease
9) Patients deemed by the investigator to be inappropriate to participate
40
1st name | Satoki |
Middle name | |
Last name | Shichijo |
Osaka International Cancer Institute
Department of Gastrointestinal Oncology
541-8567
3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan
06-6945-1181
7satoki@gmail.com
1st name | Yasuhiro |
Middle name | |
Last name | Tani |
Osaka International Cancer Institute
Department of Gastrointestinal Oncology
541-8567
3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan
06-6945-1181
y.tani1646@gmail.com
Department of Gastrointestinal Oncology, Osaka International Cancer Institute
Self funding
Self funding
Osaka International Cancer Institute
3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan
06-6945-1181
rinri01@opho.jp
NO
2023 | Year | 06 | Month | 23 | Day |
Unpublished
36
No longer recruiting
2023 | Year | 06 | Month | 06 | Day |
2023 | Year | 06 | Month | 08 | Day |
2023 | Year | 06 | Month | 26 | Day |
2024 | Year | 09 | Month | 15 | Day |
This is a single-center, prospective, observational study.
Included patients are diagnosed with familial adenomatous polyposis and undergoing or scheduled to undergo intensive downstaging polypectomy between June 2023 and June 2024.
2023 | Year | 06 | Month | 22 | Day |
2024 | Year | 06 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058527